[1]陈红霞 李嫣晓 高未潼 郑颖颖.立体定向放射治疗在心血管疾病中的应用[J].心血管病学进展,2025,(12):1086.[doi:10.16806/j.cnki.issn.1004-3934.2025.12.007]
 CHEN Hongxia,LI Yanxiao,GAO Weitong,et al.Application of Stereotactic Radiotherapy in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2025,(12):1086.[doi:10.16806/j.cnki.issn.1004-3934.2025.12.007]
点击复制

立体定向放射治疗在心血管疾病中的应用()

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2025年12期
页码:
1086
栏目:
综述
出版日期:
2025-12-25

文章信息/Info

Title:
Application of Stereotactic Radiotherapy in Cardiovascular Disease
作者:
陈红霞 李嫣晓 高未潼 郑颖颖
(新疆医科大学第一附属医院心脏中心,新疆 乌鲁木齐 830054)
Author(s):
CHEN HongxiaLI YanxiaoGAO WeitongZHENG Yingying
(Department of Cardiology,The First Affiliated Hospital of Xinjiang Medical University,Urumqi 830054,Xinjiang,China)
关键词:
立体定向放射治疗心血管疾病非侵入性放射治疗立体定向技术
Keywords:
Stereotactic radiotherapy Cardiovascular diseases Non-invasive radiotherapy Stereotactic technology
DOI:
10.16806/j.cnki.issn.1004-3934.2025.12.007
摘要:
立体定向放射治疗(SRT)作为一种非侵入性放射治疗方式,已广泛应用于肿瘤治疗领域。因SRT具有精度高、剂量集中、对周围组织损伤小等优势,已逐步将其拓展至心血管疾病领域。现结合近年SRT在心血管疾病中的临床应用案例,探讨其在心律失常、高血压、梗阻性肥厚型心肌病等疾病中的治疗前景。
Abstract:
Stereotactic radiotherapy(SRT) as a non-invasive radiotherapy method has been widely applied in the field of tumor treatment. Owing to its advantages such as high precision,concentrated dose delivery,and minimal damage to surrounding tissues,SRT has gradually expanded its application to the field of cardiovascular disease. This paper ,drawing upon recent clinical application cases of SRT in cardiovascular disorders ,delves into its therapeutic potential in various conditions,including arrhythmia,hypertension,and obstructive hypertrophic cardiomyopathy

参考文献/References:

[1] Potters L,Kavanagh B,Galvin JM,et al. American Society for Therapeutic Radiology and Oncology(ASTRO) and American College of Radiology(ACR) practice guideline for the performance of stereotactic body radiation therapy[J]. Int J Radiat Oncol Biol Phys,2010,76(2):326-332.

[2] Timmerman RD,Kavanagh BD,Cho LC,et al. Stereotactic body radiation therapy in multiple organ sites[J]. J Clin Oncol,2007,25(8):947-952.

[3] Chang JH,Cha MJ,Seo JW,et al. Feasibility study on stereotactic radiotherapy for total pulmonary vein isolation in a canine model[J]. Sci Rep,2021,11(1):12369.

[4] Loo BW Jr,Soltys SG,Wang L,et al. Stereotactic ablative radiotherapy for the treatment of refractory cardiac ventricular arrhythmia[J]. Circ Arrhythm Electrophysiol,2015,8(3):748-750.

[5] Paul CZ,Edward AG,Thomas F,et al. P1809 Noninvasive cardiac radiosurgery:current clinical experience for treatment of refractory arrhythmias[J]. Europace,2017,40(supple 1):ehz748.0500

[6] Cuculich PS,Schill MR,Kashani R,et al. Noninvasive cardiac radiation for ablation of ventricular tachycardia[J]. N Engl J Med,2017,377(24):2325-2336.

[7] Robinson CG,Samson PP,Moore KMS,et al. Phase Ⅰ/Ⅱ trial of electrophysiology-guided noninvasive cardiac radioablation for ventricular tachycardia [J]. Circulation,2019,139(3):313-321.

[8] Cuculich P.HRS 2020:Longer Term Results from the ENCORE-VT Study[Z].2020https://www.radcliffecardiology.com/video-index/hrs-2020-longer-results-encore-vt-study.

[9] Neuwirth R,Cvek J,Knybel L,et al. Stereotactic radiosurgery for ablation of ventricular tachycardia[J]. Europace,2019,21(7):1088-1095.

[10] Arkles J,Markman T,Trevillian R,et al. One-year outcomes after stereotactic body radiotherapy for refractory ventricular tachycardia[J]. Heart Rhythm,2024,21(1):18-24.

[11] van der Ree MH,Dieleman EMT,Visser J,et al. Non-invasive stereotactic arrhythmia radiotherapy for ventricular tachycardia:results of the prospective STARNL-1 trial[J]. Europace,2023,25(3):1015-1024.

[12] Miszczyk M,Hoeksema WF,Kuna K,et al. Stereotactic arrhythmia radioablation(STAR)-a systematic review and meta-analysis of prospective trials on behalf of the STOPSTORM.eu consortium [J]. Heart Rhythm,2025,22(1):80-89.

[13] Gupta A,Sattar Z,Chaaban N,et al. Stereotactic cardiac radiotherapy for refractory ventricular tachycardia in structural heart disease patients:a systematic review[J]. Europace,2024,27(1):euae305.

[14] Wei C,Boeck M,Qian PC,et al. Cost of cardiac stereotactic body radioablation therapy versus catheter ablation for treatment of ventricular tachycardia[J]. Pacing Clin Electrophysiol,2022,45(9):1124-1131.

[15] Sharma A,Wong D,Weidlich G,et al. Noninvasive stereotactic radiosurgery(CyberHeart) for creation of ablation lesions in the atrium[J]. Heart Rhythm,2010,7(6):802-810.

[16] Bode F,Blanck O,Gebhard M,et al. Pulmonary vein isolation by radiosurgery:implications for non-invasive treatment of atrial fibrillation[J]. Europace,2015,17(12):1868-1874.

[17] Monroy E,Azpiri J,De la Pe?a C,et al. Late gadolinium enhancement cardiac magnetic resonance imaging post-robotic radiosurgical pulmonary vein isolation(RRPVI):first case in the world[J]. Cureus,2016,8(8):e738.

[18] Qian PC,Azpiri JR,Assad J,et al. Noninvasive stereotactic radioablation for the treatment of atrial fibrillation:First-in-man experience[J]. J Arrhythm,2020,36(1):67-74.

[19] Bonaparte I,Gregucci F,di Monaco A,et al. Phase Ⅱ trial of LINAC-based STereotactic Arrhythmia Radioablation (STAR) for paroxysmal atrial fibrillation in elderly:planning and dosimetric point of view[J]. J Pers Med,2023,13(4) :596.

[20] Sakakura K,Tunev S,Yahagi K,et al. Comparison of histopathologic analysis following renal sympathetic denervation over multiple time points[J]. Circ Cardiovasc Interv,2015,8(2):e001813.

[21] Rousselle SD,Brants IK,Sakaoka A,et al. Neuromatous regeneration as a nerve response after catheter-based renal denervation therapy in a large animal model:immunohistochemical study[J]. Circ Cardiovasc Interv,2015,8(5):e002293.

[22] Booth LC,Nishi EE,Yao ST,et al. Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep[J]. Hypertension,2015,65(2):393-400.

[23] Cai XX ,Yang YL,Shen YC,et al. Noninvasive stereotactic radiotherapy for renal denervation in a swine model[J]. J Am Coll Cardiol,2019,74(13):1697-1709.

[24] Cai X,Shen Y,Yang Y,et al. Renal denervation by noninvasive stereotactic radiotherapy induces persistent reduction of sympathetic activity in a hypertensive swine model[J]. J Am Heart Assoc,2021,10(16):e020068.

[25] Zhu ZW,Li XP,Gao YW,et al.[Safety and feasibility of stereotactic radiation therapy on porcine ventricular septum:a preliminary study][J]. Zhonghua Xin Xue Guan Bing Za Zhi,2022,50(9):907-912.

[26] Li X ,Zhu Z,Liu J,et al. Septal radioablation therapy for patients with hypertrophic obstructive cardiomyopathy:first-in-human study[J]. Eur Heart J Open,2023,3(3):oead052.

[27]李慧洋,吴俊劼,周鹏,等. 立体定向射波刀放射治疗肥厚型心肌病的基础研究及临床探索[J].复旦学报(医学版),2022,49(3):360-368+383.

[28] Bonomo P,Cipressi S,Desideri I,et al. Stereotactic body radiotherapy with CyberKnife for cardiac malignancies[J]. Tumori,2015,101(3):294-297.

[29] Stergioula A,Pantelis E. Treatment of a primary cardiac angiosarcoma with stereotactic body radiation therapy[J]. Hellenic J Cardiol,2023,72:70-71.

[30] Dhar A,Donovan E,Leong D,et al. Stereotactic Body Radiation Therapy(SBRT) for a patient with a myocardial metastasis:a case report[J]. Curr Oncol,2021,28(1):390-395.

相似文献/References:

[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
 BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(12):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
 REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(12):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
 YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(12):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
 ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(12):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
 QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(12):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
 JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(12):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
 HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(12):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
 Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(12):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
 WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(12):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]

更新日期/Last Update: 2026-04-14